Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3, Multicenter, Randomized, Subject and Evaluator Blinded, Controlled Study Evaluating the Safety and Efficacy of NTX-001 Compared to Standard of Care (Neurorrhaphy) in the Treatment of Upper Extremity Transected Nerves Requiring Surgical Repair.

NCT06616025 is registered in ClinicalTrials.gov with Neuraptive Therapeutics Inc. as lead sponsor.

NCT NCT06616025
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06616025 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3, Multicenter, Randomized, Subject and Evaluator Blinded, Controlled Study Evaluating the Safety and Efficacy of NTX-001 Compared to Standard of Care (Neurorrhaphy) in the Treatment of Upper Extremity Transected Nerves Requiring Surgical Repair.
Lead sponsor
Neuraptive Therapeutics Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
February 10, 2025
Completion date
April 30, 2027
Enrollment
98 (estimated)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

peripheral nerve injury (pni), peripheral nerve injury upper limb